Microbot Medical Inc. 8-K

What Happened

• Microbot Medical Inc. filed a Form 8-K on June 30, 2026 announcing it entered into a Letter of Agreement with Sanmina Corporation to manufacture the Company’s LIBERTY® Endovascular Robotic System.
• The filing (Items 7.01 and 8.01) says the agreement enables Microbot to expand manufacturing capacity to meet expected demand from existing and new accounts and to support its cost reduction strategy. A press release is attached as Exhibit 99.1 and the filing includes customary forward‑looking statements.

Key Details

• Agreement counterparty: Sanmina Corporation.
• Product: LIBERTY® Endovascular Robotic System.
• Filing date: June 30, 2026 (Form 8-K, Items 7.01, 8.01, 9.01).
• The 8-K does not disclose financial terms, production timelines, or specific capacity/volume commitments; a press release (Exhibit 99.1) is included.

Why It Matters

• The company states the Sanmina agreement is intended to expand manufacturing capacity and support a cost‑reduction strategy—facts that are directly relevant to Microbot’s commercialization and cost structure going forward.
• Because the filing did not provide financial terms or timelines, investors should watch for follow‑up disclosures (production start dates, costs, and any impact on revenue or margins) to assess the agreement’s operational and financial effects.